How long do withdrawal symptoms from kratom (Mitragyna speciosa) typically last?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Kratom Withdrawal Duration

Kratom withdrawal symptoms typically last 3 to 14 days, with symptoms usually beginning within 3 days after cessation and peaking around 48-72 hours. This timeline mirrors the withdrawal pattern seen with cannabis and other substances with opioid-like properties 1.

Acute Withdrawal Timeline

The acute withdrawal phase follows a predictable course:

  • Onset: Symptoms begin within 1-12 hours after last kratom intake, depending on individual metabolism and usage patterns 2
  • Peak: Maximum symptom intensity occurs at approximately 48-72 hours 3
  • Resolution: Most acute symptoms resolve within 7-14 days 1

This timeframe is consistent with the withdrawal patterns observed for substances with partial opioid agonist activity, though kratom's unique alkaloid profile (mitragynine and 7-hydroxymitragynine) creates some variability in individual experiences.

Symptom Profile

Psychological symptoms predominate and include:

  • Irritability, restlessness, and anxiety
  • Depressed mood
  • Sleep disturbances
  • Craving for kratom
  • Loss of concentration 4

Physical symptoms are generally mild to moderate:

  • Myalgia and body aches
  • Joint pain
  • Gastrointestinal upset (diarrhea, nausea, loss of appetite)
  • Lacrimation and rhinorrhea
  • Yawning
  • Feverish sensations
  • Tremors 4

Importantly, most regular kratom users (70%) experience only mild anxiety symptoms, and 81% experience only mild depression during cessation 5. This contrasts with the more severe withdrawal profiles seen with traditional opioids.

Factors Affecting Duration and Severity

Dose-dependent effects are critical:

  • Users consuming ≥4 glasses of kratom tea daily experience more moderate depressive symptoms during withdrawal 5
  • Higher kratom dependence scores correlate with more intense withdrawal symptoms 2
  • Duration of use and frequency of daily consumption influence symptom severity 6

Important clinical distinction: Unlike traditional opioid withdrawal, kratom cessation is not life-threatening 1. The withdrawal syndrome is uncomfortable but manageable, with symptoms generally characterized as mild to moderate rather than severe.

Extended Symptoms

While acute withdrawal resolves within 2 weeks, some users may experience a secondary abstinence syndrome lasting up to 6 months, characterized by:

  • General malaise and fatigue
  • Decreased sense of well-being
  • Poor stress tolerance
  • Persistent craving 3

This protracted withdrawal phase is similar to what occurs with other substances causing physical dependence and should be anticipated when counseling patients.

Clinical Management Implications

Sublingual buprenorphine-naloxone (Suboxone) has been reported as a promising treatment for kratom detoxification and maintenance therapy 4. Alternative approaches for inpatient detoxification include intravenous clonidine or combinations of oral dihydrocodeine and lofexidine 4.

Critical caveat: The heterogeneity of kratom products, variable alkaloid content, and frequent polysubstance use among kratom users complicate clinical assessment 6, 7. Always screen for concurrent substance use, particularly opioids, benzodiazepines, and alcohol, as these will significantly alter the withdrawal presentation and management approach.

The relatively brief and mild nature of kratom withdrawal (compared to traditional opioids) should not minimize the importance of proper assessment and support, as tolerance and withdrawal remain primary features of kratom use disorder 6.

Related Questions

What should we tell a patient with HIV, B12 deficiency, chronic left‑sided low back pain, erectile dysfunction, hypercholesterolemia, testicular hypofunction, thyroid nodule, asymptomatic microscopic hematuria, and a history of opioid use who presented to the emergency department with opioid‑withdrawal‑type symptoms after taking bupropion (Wellbutrin) and who reports heavy kratom use, that they should stop kratom, consider inpatient detoxification (potentially covered by Oscar insurance), and how to manage their other medical conditions?
How should kratom withdrawal be managed in an adult patient who has stopped regular use and presents with anxiety, irritability, insomnia, myalgia, nausea, vomiting, diarrhea, and diaphoresis?
After discontinuing kratom (Mitragyna speciosa) use, what is the minimum safe interval before undergoing general anesthesia?
What are the side effects and potential adverse effects of kratom use?
What are the signs and symptoms of kratom use?
What is the recommended starting dose of secukinumab (Secukinumab) and ixekizumab (Ixekizumab) for an adult with psoriatic arthritis who has failed two tumor necrosis factor (TNF) inhibitors and a Janus kinase (JAK) inhibitor?
What is the recommended treatment approach for alcohol use disorder, including medically supervised detoxification, pharmacologic options (e.g., naltrexone, disulfiram, acamprosate) and psychosocial therapies?
In a patient with an acute respiratory infection who is already on azithromycin, budesonide inhaler (Budcort), and paracetamol, should acebrophylline or N‑acetylcysteine be added to the regimen?
Is Escherichia coli causing a urinary tract infection susceptible to fosfomycin?
In a 46-year-old Asian male, what is the clinical significance of a spot urine creatinine of 429 mg/dL and an eosinophil count of 663 cells/µL?
Should theophylline be added to the treatment regimen of a patient with an acute respiratory infection who is already receiving azithromycin, inhaled budesonide (Budcort), and paracetamol?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.